Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT03793166
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- NCT03793166 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on NCT03793166 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03793166 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm A (nivolumab) · Active comparator
- Arm B (nivolumab, cabozantinib) · Experimental
- Enrollment
- 1,175 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 7, 2019
- Primary completion
- Mar 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03793166 · updated Oct 26, 2026
Publications
linked from the registry- Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available. PubMed 35383907
- Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18. PubMed 35304832